Invited presentation titled “VM2 Methodology and Software for Calculation of Binding Free Energies: Application to Protein-Ligand and Host-Guest Systems” given by Dr. Simon Webb at the Advanced Biomedical Computing Center, SAIC-Frederick.
VeraChem’s software now licensed to over 500 academic researchers worldwide.
VeraChem’s protein-ligand binding affinity prediction software package VM2 applied to the study of p38a MAP kinase. “Insights from Free-Energy Calculations: Protein Conformational Equilibrium, Driving Forces, and Ligand-Binding Modes”, Biophysical Journal 103(2): 342-351. DOI: 10.1016/j.bpj.2012.05.046
Phase I milestones successfully completed, NIH awards VeraChem Phase II funding for the SBIR titled, “Multilevel Parallelization of Software for Accurate Protein-Ligand Affinities.”
Paper describing VeraChem’s protein-ligand binding affinity method VM2 published. “Modeling Protein-Ligand Binding by Mining Minima”, Journal of Chemical Theory and Computation 6(11): 3540-3557. DOI: 10.1021/ct100245n
VeraChem licenses its novel protein-ligand binding affinity software to a major pharmaceutical company.
VeraChem awarded fast-track SBIR to enhance the performance of its novel binding affinity software through parallelization. “Multilevel Parallelization of Software for Accurate Protein-Ligand Affinities”
VeraChem establishes contract research agreement with a major pharmaceutical company to apply VeraChem’s unique computational chemistry software.
VeraChem and a major home products company establish contract research agreement involving application of VeraChem’s software.
VeraChem and local biotech company engage in contract research agreement.
© 2007-2023 VeraChem, LLC
